Insolvency is the last stage of a sequence that starts in the boardroom. Directors who know the four stages, and where AI speeds them, can interrupt the sequence while options are still wide.

Companies that sustain high performance share a set of habits. Several of the cases first used to illustrate them later reversed, which is why boards should watch the evidence and warning signs for each habit rather than the story.

Strategy tools do not make strategy. A board that knows what each tool shows, and what it leaves out, can see whether the strategy is sound, carried out, and supported across the organization.

Most new ventures in healthcare and life sciences fail for reasons visible early. Ten principles test a young company, and the same ten test every AI approval.

A reduction in workforce can protect an organization or quietly remove the capabilities it needs next. The difference lies in whether it follows a strategy.

The EU AI Act is law, and the July 2026 Digital Omnibus pushed its high-risk deadlines to 2027 and 2028. The delay is the risk: the inventory, vendor terms, and technical files it requires take longer to build than the time it buys.

Most acquisitions that disappoint fail for reasons that were visible before the vote. The board does not need to run the tools that expose them; it needs to see what the tools found before it approves the deal.

The FDA's January 2025 draft guidance on AI used to support drug and biologic submissions is still a draft, but regulators, partners, and acquirers already expect the evidence it describes. This article explains the framework, what has changed since, and what boards should ask management to show.

Health system boards do not need to understand how AI models work. They need to know which uses serve how the organization is paid, what each kind of model demands after approval, which standards they will be measured against, and who is accountable.

A turnaround tests a board more than any other period. Its work intensifies but remains oversight: scenarios with triggers, tests of every cut against viability and patients, and conditions on AI approvals.